- Home
- ABBV vs ABT Comparison
ABBV vs ABT Comparison
Compare ABBV & ABT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABBV | ABT |
|---|---|---|
| Founded | 2012 | 1888 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.5B | 152.9B |
| IPO Year | 2012 | 2006 |
Fundamental Metrics
Financial Performance| Metric | ABBV | ABT |
|---|---|---|
| Price | $221.58 | $88.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 20 |
| Target Price | ★ $253.71 | $130.90 |
| AVG Volume (30 Days) | 3.6M | ★ 9.0M |
| Earning Date | 04-29-2026 | 04-16-2026 |
| Dividend Yield | ★ 3.39% | 2.76% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.39 | ★ 0.61 |
| Revenue | ★ $61,160,000,000.00 | $44,328,000,000.00 |
| Revenue This Year | $11.87 | $10.75 |
| Revenue Next Year | $8.12 | $8.10 |
| P/E Ratio | $583.67 | ★ $144.56 |
| Revenue Growth | ★ 8.57 | 5.67 |
| 52 Week Low | $181.75 | $81.97 |
| 52 Week High | $244.81 | $137.49 |
Technical Indicators
Market Signals| Indicator | ABBV | ABT |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 48.72 |
| Support Level | $220.11 | $84.96 |
| Resistance Level | $230.91 | $89.34 |
| Average True Range (ATR) | 5.05 | 1.85 |
| MACD | 0.40 | 0.45 |
| Stochastic Oscillator | 61.55 | 49.42 |
Price Performance
Historical ComparisonAbout ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
About ABT Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.